Prolight Diagnostics

Warrants of series TO7 were exercised to approximately 96.4 percent and Prolight Diagnostics receives approximately SEK 12.6 million Read the full press release at: https://lnkd.in/dWNgVGgC

BioStock - Connecting Innovation and Capital published an article "Prolight eyes business opportunity for plasma separation method" Prolight Diagnostics has secured European patent approval for its method for separating plasma from whole blood, utilized in the MicroFlex system. This separation technology presents a business opportunity as it can be integrated into other systems and adapted for use with various sample types. To gain deeper insights into the technology, BioStock contacted the company’s development partner, TTP. Read the full article at: https://lnkd.in/dQ62Qc4T

BioStock - Connecting Innovation and Capital published an article: Prolight’s COO: “The pilot line sets the stage for scalability” Prolight Diagnostics recently completed a business review of the pilot manufacturing line at its partner, FlexMedical Solutions. The production line will supply cartridges for the upcoming clinical performance study of the Psyros POC platform and facilitate a seamless transition to full-scale commercial production. Prolight’s COO, Karl Bullen, shared insights into the progress and next steps. Psyros is Prolight Diagnostics’ digital point-of-care platform designed to detect low levels of troponin in the blood, providing a fast and reliable diagnostic tool for myocardial infarction. The system consists of a portable analyzer and a single-use cartridge. Only a small drop of blood is required to perform the test. Read the full article: https://lnkd.in/eP-8BsfR

Prolight obtains patent potentially representing a new business opportunity Prolight Diagnostics has obtained a European patent based on a cutting-edge solution for separating plasma from whole blood within a fluidic consumable. The separation generates high quality plasma, requires minimal physical space, and is completed in a short time, which opens new potential business opportunities by incorporating the technology into other disposable fluidic systems. The separation method is a further development of conventional technology that is widely used in the analysis of blood samples in hospital laboratories. Importantly, this method is compatible with larger input sample volumes than typical plasma separation membranes, enabling the detection of more novel analytes. This means that the separation technology could serve as a distinct business opportunity for incorporation into various systems for measuring such components in a range of potential sample matrices, including blood, spinal fluid and faecal samples, even outside MicroFlex. The separation method was developed in connection with the development of the point of care system MicroFlex, now further developed by Prolight's development partner The Technology Partnership (TTP). “The extensive potential applications of this separation technology, even outside MicroFlex, further strengthen the commercial discussions that TTP is conducting,” said Ulf Bladin, CEO of Prolight Diagnostics. “It is excellent to see this patent granted. It confirms the technology’s position as a unique solution to the challenge of medium volume blood processing. A number of potential clients are excited by the approach as part of a number of different diagnostic workflows and we have even had discussions regarding taking the technology into space,” said Giles Sanders Head of Diagnostics at TTP. Link to the press release: https://lnkd.in/dRRFHe4F

BioStock - Connecting Innovation and Capital publishes the article "Point-of-Care in the spotlight at Cardiac Markers Dialogue Meeting" Prolight Diagnostics recently participated at the 2024 Cardiac Markers Dialogue Meeting in Glasgow, UK. This meeting brought together leading researchers and healthcare professionals specializing in cardiology and cardiac biomarker-based diagnostics. “We showcased our innovative point-of-care platform, Psyros, to aid rapid diagnosis of myocardial infarction, while engaging in discussions on the latest advancements in the field”, said Prolight’s CSO, Dr. Aileen McGettrick. Link to the article: https://lnkd.in/dSsGUbxM

Prolight Diagnostics publishes its investor letter for September 2024. The letter includes updates on the rapid and cost-effective development of our proprietary, unique digital point-of-care analysis system, Psyros™, as well as several important external activities. link to the investor letter: https://lnkd.in/drj9k8bd

Prolight showcases Psyros™ to global key opinion leaders in cardiology at 2024 Cardiac Markers Dialogue Meeting Prolight Diagnostics today announces its participation at the 2024 Cardiac Markers Dialogue Meeting, on 26th September and 27th September in Glasgow, UK. This prestigious event brings together key opinion leaders including leading researchers and healthcare professionals, to discuss advances in cardiac biomarker diagnostics and their implications for patient care. The 2024 meeting provides an invaluable platform for Prolight to showcase its single molecule counting POC platform PsyrosTM and engage in dialogue with experts. It is also an opportunity to gain insight to state of the art on critical topics such as advances in biomarker research, their use in early detection of cardiac events, and the integration of new technologies in clinical practice. “Our commitment to advancing rapid diagnosis of potential myocardial infarction at the point of care aligns perfectly with the goals of the Dialogue Meeting. We look forward to engaging with fellow professionals, sharing our technology, and fostering collaborations that can lead to improved outcomes for patients worldwide. We are honoured to sponsor this important event,” said Dr Aileen McGettrick, CSO of Prolight. The Cardiac Markers Dialogue Meeting will feature keynote speakers, panel discussions, and workshops designed to enhance understanding and application of cardiac markers in clinical practice. For more information about the 2024 Cardiac Markers Dialogue Meeting, please visit Cardiac Marker Dialogues – Cardiac Marker Dialogues (cmdmeeting.org.uk) Link to press release: https://lnkd.in/ddGTJ9bD

Prolight conducts business review at FlexMedical Solutions In September, Prolight conducted a business review at its contract manufacturing partner for the cartridge, FlexMedical Solutions (FMS) in Livingston, UK. The review included a progress update and an inspection of the pilot cartridge manufacturing line and associated support facilities. “It was exciting to see the significant progress FMS has made over the last few months. With building works now complete, it was great to see the first wave of production equipment being installed” said COO Karl Bullen “We are very proud of our facilities and our team and as such it is always a privilege to host our clients. The dedicated Prolight production suite is really taking shape and we are excited to take receipt of the remaining manufacturing equipment in the coming months” said Murray Whyte, CTO. The pilot line at FMS is being commissioned to support the regulatory approvals including the clinical performance study and volumes for commercial launch. With the ability to produce hundreds of thousands of cartridges at a competitive cost of goods, the technologies and processes being developed by FMS are designed to be scalable with future high levels of automation, thus enabling a swift transition to full-scale commercial production.

BioStock - Connecting Innovation and Capital publishes the article "Prolight Diagnostics advances towards validation of test for myocardial infarction diagnostics" Prolight Diagnostics’ report for the second quarter marks significant progress in developing the point-of-care analysis system Psyros. Not least, the company received a British grant of SEK 17 million, allowing them to initiate a pre-validation study on whole blood samples from patients with suspected myocardial infarction. The first results from the study are expected in the fourth quarter of 2024. Read the full article here: https://lnkd.in/dM8SNhXz

Emergers publicerar uppdaterad analys om Prolight Diagnostics där de står fast vid ett motiverat värde om 1,1-1,2 kronor per aktie. Läs artikeln här: https://lnkd.in/dWB7zXGM